Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study
- PMID: 20888520
- DOI: 10.1016/j.jacc.2010.03.090
Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study
Abstract
Objectives: The primary objective of this study was to assess the effect of a 6-month testosterone supplementation therapy on functional capacity and insulin resistance in female patients with chronic heart failure (CHF).
Background: Patients with CHF show decreased exercise capacity and insulin sensitivity. Testosterone supplementation improves these variables in men with CHF. No study has evaluated the effects of testosterone supplementation on female patients with CHF.
Methods: Thirty-six elderly female patients with stable CHF, (ejection fraction 32.9 ± 6) were randomly assigned (2:1 ratio) to receive testosterone transdermal patch (T group, n = 24) or placebo (P group, n = 12), both on top of optimal medical therapy. At baseline and after 6 months, patients underwent 6-min walking test (6MWT), cardiopulmonary exercise test, echocardiogram, quadriceps maximal isometric voluntary contraction, dynamic quadriceps isokinetic strength (peak torque), and insulin resistance assessment by homeostasis model.
Results: Distance walked at 6MWT as well as peak oxygen consumption significantly improved in the T group, whereas they were unchanged in the P group (p < 0.05 for all comparisons). The homeostasis model was significantly reduced in the T group in comparison with the P group (-16.5% vs. +5%, respectively; p < 0.05). Maximal voluntary contraction and peak torque increased significantly in the T group but did not change in the P group. Increase in distance walked at 6MWT was related to the increase in free testosterone levels (r = 0.593, p = 0.01). No significant changes in echocardiographic parameters were observed in either group. No side effects requiring discontinuation of T were detected.
Conclusions: Testosterone supplementation improves functional capacity, insulin resistance, and muscle strength in women with advanced CHF. Testosterone seems to be an effective and safe therapy for elderly women with CHF.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Testosterone therapy in women with heart failure "why can't a woman be more like a man?".J Am Coll Cardiol. 2010 Oct 12;56(16):1317-9. doi: 10.1016/j.jacc.2010.03.091. J Am Coll Cardiol. 2010. PMID: 20888521 No abstract available.
Similar articles
-
Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.Eur Heart J. 2006 Jan;27(1):57-64. doi: 10.1093/eurheartj/ehi443. Epub 2005 Aug 10. Eur Heart J. 2006. PMID: 16093267 Clinical Trial.
-
Heart failure therapy: testosterone replacement and its implications.Eur Heart J. 2006 Jan;27(1):10-2. doi: 10.1093/eurheartj/ehi653. Epub 2005 Nov 16. Eur Heart J. 2006. PMID: 16291772 No abstract available.
-
A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.J Am Coll Cardiol. 2010 May 4;55(18):1907-14. doi: 10.1016/j.jacc.2009.12.044. J Am Coll Cardiol. 2010. PMID: 20430261 Clinical Trial.
-
Testosterone supplementation in heart failure: a meta-analysis.Circ Heart Fail. 2012 May 1;5(3):315-21. doi: 10.1161/CIRCHEARTFAILURE.111.965632. Epub 2012 Apr 17. Circ Heart Fail. 2012. PMID: 22511747 Review.
-
Hormone replacement therapy in heart failure.Curr Opin Cardiol. 2015 May;30(3):277-84. doi: 10.1097/HCO.0000000000000166. Curr Opin Cardiol. 2015. PMID: 25807222 Review.
Cited by
-
Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations.J Clin Invest. 2024 Sep 3;134(17):e180073. doi: 10.1172/JCI180073. J Clin Invest. 2024. PMID: 39225098 Free PMC article. Review.
-
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.Eur Heart J. 2024 Oct 5;45(37):3789-3800. doi: 10.1093/eurheartj/ehae479. Eur Heart J. 2024. PMID: 39185895 Free PMC article. Clinical Trial.
-
The Impact of Testosterone Therapy on Cardiovascular Risk Among Postmenopausal Women.J Endocr Soc. 2023 Oct 25;8(1):bvad132. doi: 10.1210/jendso/bvad132. eCollection 2023 Dec 1. J Endocr Soc. 2023. PMID: 38178905 Free PMC article. Review.
-
Endogenous Sex Hormone Levels and Myocardial Fibrosis in Men and Postmenopausal Women.JACC Adv. 2023 May;2(3):100320. doi: 10.1016/j.jacadv.2023.100320. Epub 2023 May 10. JACC Adv. 2023. PMID: 37691970 Free PMC article.
-
The treatment of chronic anemia in heart failure: a global approach.Clin Res Cardiol. 2024 Aug;113(8):1117-1136. doi: 10.1007/s00392-023-02275-4. Epub 2023 Sep 3. Clin Res Cardiol. 2024. PMID: 37660308 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
